Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
Resistance to endocrine therapy is a significant therapeutic challenge in the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy have been shown to improve progression free survival, overall response rate and clinical benefit rate in women with HR+ HER2- metastatic breast cancer compared with endocrine therapy alone. This review examines the clinical evidence to support the use of CDK4/6 inhibitors in first and second line settings. Practical guidance is provided for the use of CDK4/6 inhibitors, including tolerability data, monitoring requirements and management of key toxicities for each of the available agents.
|ISBN||1743-7563 (Electronic) 1743-7555 (Linking)|
|Authors||Boyle, F.; Beith, J.; Burslem, K.; de Boer, R.; Hui, R.; Lim, E.; McCarthy, N.; Redfern, A.; Woodward, N.|
|Responsible Garvan Author|
|Publisher Name||Asia-Pacific Journal of Clinical Oncology|
|Published Volume||14 Suppl 4|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/30288930|